Navigation Links
EpiCept Corporation to Present New NP-1 Data at American Pain,Society Meeting

itionally, the study met the following secondary endpoints: a responder analysis of improvement in pain intensity (p<0.025), a responder analysis of improvement in pain relief (p<0.01), improvement in patient sleep scores (p=0.028) and overall patient global satisfaction (p=0.04). This study also found that significant neuropathic pain relief was achieved at a small fraction of the plasma levels observed after systemic dosing. The cream was found to be safe and well tolerated across all age groups studied.

"These findings add to a growing body of clinical data which demonstrate the potential for NP-1 to provide effective, additive, long-term relief to the 15 million Americans who suffer from the pain of peripheral neuropathies. The outcome from the pharmacokinetic trial in particular supports the safety of NP-1 topical cream and even more importantly its ability to be added to orally administered therapies," remarked Jack Talley, President and CEO of EpiCept. "We believe NP-1 has the largest market potential of any of our pain product candidates and we are focused on advancing it through its current Phase IIb trials. These trials are progressing as expected and we remain on track to be able to share preliminary results from the first trial by the fourth quarter of 2007.

"Current systemically-delivered analgesics have well documented limitations and significant potential side effects. The local mechanism of action of NP-1 demonstrated in these studies could reduce these side effects by blocking pain directly at its source," remarked Stephane Allard, MD, Chief Medical Officer.

EpiCept NP-1 is currently undergoing two Phase IIb trials, enrolling a total of 700 patients. The first trial is a 200 patient, placebo-controlled study of NP-1 in patients with diabetic peripheral neuropathy (DPN). More patients suffer from DPN than any other type of neuropathic pain. Only two medications are currently approved for this use. The trial is intended to confirm
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
2. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
3. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
4. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
5. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
6. The Past, Present and Future of HLA Typing
7. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
10. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
11. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
Post Your Comments:
(Date:12/16/2009)... SOLON, Ohio, Dec. 16 HDT Engineered ... next generation technologies and a principal subcontractor for ... (MPL), led development of new anthropromorphic arm technology ... a prosthetic arm and hand, including a sense ... Defense Advanced Research Projects Agency (DARPA) Revolutionizing Prosthetics ...
(Date:12/16/2009)... 16 A new application ... the clinical review of specialty pharmaceuticals has increased ... drugs reviewed while reducing costs. ,, AIM, a ... with health plan clients representing over 35 million ... (NYSE: WLP ), adapted the successful ...
(Date:12/16/2009)... Dec. 16 EuroPharma, Inc. signs ... the use of super absorbency BCM-95® curcumin ... formulations. The exclusive distribution territory for ... food store channel and professional channel, which ... clinics. BCM-95® is a highly absorbable ...
Breaking Medicine Technology:HDT Develops Robotic Arm Technology for DARPA's Revolutionizing Prosthetics 2009 Program 2American Imaging Management's New Specialty Drug Program Delivers Immediate Results 2American Imaging Management's New Specialty Drug Program Delivers Immediate Results 3American Imaging Management's New Specialty Drug Program Delivers Immediate Results 4EuroPharma Exclusive Distributor of BCM-95 and BosPure 2EuroPharma Exclusive Distributor of BCM-95 and BosPure 3Researcher says microchannels could advance tissue engineering methods 9601 1Researcher says microchannels could advance tissue engineering methods 9601 2Researcher says microchannels could advance tissue engineering methods 9601 3Researcher says microchannels could advance tissue engineering methods 9601 4Wyeth Announces Full Redemption of Floating Rate Convertible Senior Debentures Due 2024 54657 1Wyeth Announces Full Redemption of Floating Rate Convertible Senior Debentures Due 2024 54657 2Wyeth Announces Full Redemption of Floating Rate Convertible Senior Debentures Due 2024 54657 3Wyeth Announces Full Redemption of Floating Rate Convertible Senior Debentures Due 2024 54657 4Chicago Mayor Honors Astellas Excellence in Learning Development 54654 1Chicago Mayor Honors Astellas Excellence in Learning Development 54654 2
... - ZIOPHARM,Oncology, Inc. (NASDAQ: ZIOP) announces that ... trial of ZIO-201 (isophosphoramide mustard,- IPM) to ... the,European Society of Medical Oncology (ESMO) meeting ... abstract entitled, "Phase-I/II,Study of IPM (ZIO-201) In ...
... Late-breaking Phase III,clinical trial data presented today ... Haemostasis (ISTH) Congress demonstrate,that once-daily rivaroxaban achieved ... (VTE) in patients undergoing,knee replacement surgery in ... of care. Patients in the RECORD3,(REgulation of ...
Other Medicine Technology:Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 2Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 3Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 2Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 3Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 4Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 5
(Date:12/16/2009)... half, but use in humans is still far off , , ... nature, researchers have built and tested synthetic versions of the ... other cases where blood just won,t stop flowing. , "We ... in degradable stitches, which dissolve in the body," said Erin ... Reserve University, and lead author of a report published ...
(Date:12/16/2009)... Substance Specific Neurological Stress Reduction Therapy or NSRTSM is found ... chronic conditions such as allergies, asthma, migraines, chronic fatigue and ... practices throughout the country are using this holistic therapy including ... ... Minneapolis, MN (Vocus) December 14, 2009 ...
(Date:12/16/2009)... government report finds , , WEDNESDAY, Dec. 16 (HealthDay News) ... 45.4 million Americans of all ages -- or 15.1 ... according to new National Health Interview Survey statistics released ... of all ages had been uninsured for at least ... 31.9 million (10.6 percent) had been uninsured for more ...
(Date:12/16/2009)... -- OrthoAccel Technologies, Inc., developers of the ... to enhance orthodontics, announced Alison Davies as its ... Ms. Davies has spent the last fourteen years ... most recently for nine years as a senior ... Invisalign . ,, (Logo: ...
(Date:12/16/2009)... Calif., Dec. 16 New research ... bioactive compounds in pistachios, and molecules present ... Pistachio oil decreases levels of an inflammatory ... tetratricopeptide repeats 2). Inflammation is a complex ... cells or irritants, and it underlies functional ...
Breaking Medicine News(10 mins):Health News:Synthetic Platelets Put the Brakes on Blood Loss 2Health News:Synthetic Platelets Put the Brakes on Blood Loss 3Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 2Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 3Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 4Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 5Health News:Over 45 Million Americans Now Lack Health Insurance 2Health News:Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom 2Health News:Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom 3Health News:Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom 4Health News:New Study Reveals Pistachios Have Anti-Inflammatory Properties 2Health News:New Study Reveals Pistachios Have Anti-Inflammatory Properties 3
... medicine may no longer be truly alternative shows ... 34,000 readers. The report revealed that Chiropractic was ... drugs, // by readers with back pain. Deep-tissue ... treating osteoarthritis and fibromyalgia. While readers suffering from ...
... Aliskiren can possibly be the latest method of ... from early studies of aliskiren indicate that the ... for patients with mild-to-moderate uncomplicated // essential high ... trials also suggest that the new medication is ...
... for preventing pregnancies have recently also been under intense ... sexually transmitted diseases (e.g. Gonorrhea and 25 other related ... protection even the most famous lover of all, Casanova ... birth control and for protection against infection. The question ...
... tragedies of our society that persons infected with HIV/AIDS not ... which any person with any illness must do - but ... // . ,Our attitude to the disease rests largely ... campaigns that has been conducted so far. Infact, a hardened ...
... video games and use violent moves such as karate kicks ... study by Kevin Kieffer and Jessica Nicoll of Saint Leo ... up' video games // and how children and adolescents ... online edition of science journal Nature. ,Some researchers had ...
... the available data, the introduction of chicken doctors because ... of hospitalizations and visits to pox // . The ... subject. ,Varicella vaccine is recommended for routine immunization ... older susceptible children and adults in the United States, ...
Other Medicine News:Health News:Aliskiren: A New Treatment For Hypertension 2Health News:"An Armour against pleasure, and a cobweb against infection" – Has the condom withstood the test of time 2Health News:"An Armour against pleasure, and a cobweb against infection" – Has the condom withstood the test of time 3Health News:"An Armour against pleasure, and a cobweb against infection" – Has the condom withstood the test of time 4Health News:Chicken Pox Hospitalizations Are Becoming Less 2
Blunt tipped forceps with long thin tips (3 mm) angled at approximately 120. For grasping of subretinal membranes. Color Coding: Gold....
Blunt tipped forceps with entire interior surface of tip serrated. For general purpose membrane grasping (coarse membranes)....
Microforceps: Claes ILM Forceps...
0,6 mm (23 gauge) blunt tipped forceps with entire interior surface of tip serrated. For general purpose membrane grasping (coarse membranes)....
Medicine Products: